Vesigen, Inc.

Vesigen, Inc. is a biotechnology company focused on developing innovative therapies through epigenetic reprogramming, addressing age-related conditions and enhancing cellular function using advanced delivery platforms. Vesigen, Inc. was founded in 2019 and is based in Cambridge, US.

The company specializes in epigenetic reprogramming therapies. Robert Millman serves as both the founder and CEO. Vesigen raised USD 28. 5 mn in a Series A funding round on July 22, 2020, led by Leaps by Bayer and Morningside Group, with contributions from Alexandria Venture Investments and Linden Lake Venture Capital.

This funding round accounted for the total amount raised by the company so far. Vesigen, Inc. specializes in epigenetic reprogramming therapies aimed at restoring cellular function and addressing age-related conditions. The core product offerings include the ERA® technology, which uses mRNA to influence the cellular epigenome, and the eTurna® lipid nanoparticle (LNP) delivery platform designed for targeted therapy delivery.

The company has recently acquired the ARMMs (ARRDC1 Mediated Microvesicles) technology, enhancing its delivery capabilities for larger and more diverse therapeutic cargoes. Vesigen primarily targets applications in dermatology, ophthalmology, and immunology, addressing issues such as skin aging, eyesight loss, and muscle wasting, with a focus on markets in North America and Europe. Vesigen operates on a transactional model that involves partnerships and collaborations with academic institutions and commercial entities. Revenue is generated through licensing agreements, allowing clients access to proprietary technologies like the ARMMs delivery platform and the eTurna LNP system.

These agreements may involve upfront payments alongside milestone payments contingent on clinical development and product commercialization successes, particularly through partnerships with pharmaceutical companies aiming to integrate Vesigen's delivery systems into their products. Vesigen plans to utilize the USD 28. 5 mn raised in the Series A funding round to support the development of new products and enhance its market presence. The company aims to expand into new geographic markets, specifically targeting regions in North America and Europe, with strategic initiatives expected to unfold as the company progresses in its developmental timeline.

The funding will be directed towards advancing clinical trials and optimizing product offerings, with particular emphasis on the launch of innovative therapies designed to restore cellular function.